Researchers have found that losartan, an angiotensin II receptor blocker, can protect diabetic patients with nephropathy from end-stage renal disease. They say their findings, if put into action, could have widespread public health and economic effects.
“Treatment with losartan in patients with type 2 diabetes and nephropathy not only reduces the incidence of end-stage renal disease, but also may result in substantial cost savings,” said William Gerth, a researcher with Merck & Co., Inc., New Jersey, United States. Dr. Gerth and colleagues presented these findings at the 24th annual congress of the European Society of Cardiology (ESC) in Berlin, Germany.
Using data developed during the RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) trial, Dr. Gerth estimated that in countries within the European Union, treatment of patients with losartan would produce a savings of 5,189 euros after four years. That is based on a cost estimate of 8,420 euros for 3.5 years of treatment. Dr. Gerth estimated that the end-stage renal disease cost over the same period for placebo patients was about 12,138 euros.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!